Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > I wonder if the market
View:
Post by Oden6570 on Apr 12, 2021 9:15am

I wonder if the market

Realize the upside of our tech. I mean Canada's main lab for virus research assisting and leading research to develop vaccine for the whole family of covid and other viruses This company has become much more valuable IMHO.
Comment by 99942Apophis on Apr 12, 2021 9:41am
Oden6570 wrote Realize the upside of our tech. I mean Canada's main lab for virus research assisting and leading research to develop vaccine for the whole family of covid and other viruses This company has become much more valuable IMHO. True enough Oden6570, it is baffling, my thoughts are maybe once media and stock analysts bring it to the forefront and its viewed as an incredible solution ...more  
Comment by StevenBirch on Apr 12, 2021 10:01am
Correct, we "the few" do know it's capabilities and are emotionally attached to it but I think for this to catch fire we just need some results - updates on those that have been treated and additional enrollment numbers for starters - and they should come soon. I think the last 2 announcements have put a rock solid floor under the stock but when we get good results I think they will ...more  
Comment by CancerSlayer on Apr 12, 2021 10:35am
  Hey SB...I'm pretty full too, but this is turning into a buffet & there's always room for a little more dessert.  I plan to gorge a little on each new set of promising results (preclinical &/or clinical), especially when they're coming in from potentially "multiple" delicious indications.  Your feeling "morbidly obese" is another' ...more  
Comment by StevenBirch on Apr 12, 2021 10:54am
Fat and jolly works for me!
Comment by Rumpl3StiltSkin on Apr 12, 2021 10:55am
To Thors original question, No! They(markets) still need to connect the dots. TLT deserves a speculative rating, especially with all that is known over the last 3 weeks, above $1. We have 'on good authority' that TLT is still under major consideration for that 2nd Lumeda phase 1 trial. They are now working with Canadas national lab on a Covid 19 vaccine/therapy. Li Ka Shing Institute has ...more  
Comment by Oilminerdeluxe on Apr 12, 2021 11:08am
I'll let him know.
Comment by Rumpl3StiltSkin on Apr 12, 2021 11:58am
When the data from this Covid effort come in later this year, and more data from the Cancer fronts, who knows what the spec value will/should/ be....?
Comment by 99942Apophis on Apr 12, 2021 12:20pm
Rumpl3StiltSkin wrote When the data from this Covid effort come in later this year, and more data from the Cancer fronts, who knows what the spec value will/should/ be....? Ok Rumpl3StiltSkin on speculation should we get hard numbers and what most people on this board think my wild guess falls into a wide range between 15 and 19 dollars that is with a high multiple awarded for the future PE ...more  
Comment by Rumpl3StiltSkin on Apr 12, 2021 12:32pm
I actually think that the Covid angle could get us to those valuations first, mostly on spec. 1433 could be the 6th or 7th Vaccine to get approved. It will be first amongst it's peers though in that it will also be an effective therapy and will not need any updates for future strains. It's only downside is it probably doesn't confer t-cell immunity, but I'm not sure about that.
Comment by CancerSlayer on Apr 12, 2021 12:34pm
  I'd be shocked if Roswell/Lumeda don't incorporate TLD-1433.  The question is, which news will we hear first imo....animal data or a new trial using TLD-1433?  Will be hard to hold this sp down much longer with so many coals in this fire.  I also hope our new public/private collaboration re: vaccine development isn't too unidimensional from a scientific ...more  
Comment by 2for1split on Apr 12, 2021 9:51am
You have to think that lab would be prioritzing best candidates for their work as well, considering the enormity of the situation. Lots of positives here.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250